420 related articles for article (PubMed ID: 26243735)
1. Apremilast for the treatment of psoriasis.
Chimenti MS; Gramiccia T; Saraceno R; Bianchi L; Garofalo V; Buonomo O; Perricone R; Chimenti S; Chiricozzi A
Expert Opin Pharmacother; 2015; 16(13):2083-94. PubMed ID: 26243735
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.
Bianchi L; Del Duca E; Romanelli M; Saraceno R; Chimenti S; Chiricozzi A
Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1121-8. PubMed ID: 27376729
[TBL] [Abstract][Full Text] [Related]
3. Apremilast for the management of moderate to severe plaque psoriasis.
Vangipuram R; Alikhan A
Expert Rev Clin Pharmacol; 2017 Apr; 10(4):349-360. PubMed ID: 28276777
[TBL] [Abstract][Full Text] [Related]
4. A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast.
Chiricozzi A; Caposiena D; Garofalo V; Cannizzaro MV; Chimenti S; Saraceno R
Expert Rev Clin Immunol; 2016; 12(3):237-49. PubMed ID: 26692125
[TBL] [Abstract][Full Text] [Related]
5. Drug safety evaluation of apremilast for treating psoriatic arthritis.
Busa S; Kavanaugh A
Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
[TBL] [Abstract][Full Text] [Related]
6. Safety evaluation of apremilast for the treatment of psoriasis.
Dattola A; Del Duca E; Saraceno R; Gramiccia T; Bianchi L
Expert Opin Drug Saf; 2017 Mar; 16(3):381-385. PubMed ID: 28132578
[TBL] [Abstract][Full Text] [Related]
7. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
Ohtsuki M; Okubo Y; Komine M; Imafuku S; Day RM; Chen P; Petric R; Maroli A; Nemoto O
J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657
[TBL] [Abstract][Full Text] [Related]
8. Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.
Gooderham M; Papp K
BioDrugs; 2015 Oct; 29(5):327-39. PubMed ID: 26481941
[TBL] [Abstract][Full Text] [Related]
9. Apremilast as a treatment for psoriasis.
Shutty B; West C; Pellerin M; Feldman S
Expert Opin Pharmacother; 2012 Aug; 13(12):1761-70. PubMed ID: 22712800
[TBL] [Abstract][Full Text] [Related]
10. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
Keating GM
Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
[TBL] [Abstract][Full Text] [Related]
11. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
Deeks ED
Drugs; 2015 Aug; 75(12):1393-403. PubMed ID: 26220911
[TBL] [Abstract][Full Text] [Related]
12. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
Bissonnette R; Pariser DM; Wasel NR; Goncalves J; Day RM; Chen R; Sebastian M
J Am Acad Dermatol; 2016 Jul; 75(1):99-105. PubMed ID: 27021239
[TBL] [Abstract][Full Text] [Related]
13. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
Papp K; Reich K; Leonardi CL; Kircik L; Chimenti S; Langley RG; Hu C; Stevens RM; Day RM; Gordon KB; Korman NJ; Griffiths CE
J Am Acad Dermatol; 2015 Jul; 73(1):37-49. PubMed ID: 26089047
[TBL] [Abstract][Full Text] [Related]
14. An update on the safety of apremilast for the treatment of plaque psoriasis.
Shavit E; Shear NH
Expert Opin Drug Saf; 2020 Apr; 19(4):403-408. PubMed ID: 32182143
[No Abstract] [Full Text] [Related]
15. Real-world use of apremilast for patients with psoriasis in Japan.
Kishimoto M; Komine M; Hioki T; Kamiya K; Sugai J; Ohtsuki M
J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis.
Pincelli C; Schafer PH; French LE; Augustin M; Krueger JG
J Drugs Dermatol; 2018 Aug; 17(8):835-840. PubMed ID: 30124722
[TBL] [Abstract][Full Text] [Related]
17. Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis.
Torres T; Puig L
Am J Clin Dermatol; 2018 Feb; 19(1):23-32. PubMed ID: 28597182
[TBL] [Abstract][Full Text] [Related]
18. Apremilast in psoriatic arthritis.
Schett G
Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S98-100. PubMed ID: 26472278
[TBL] [Abstract][Full Text] [Related]
19. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.
Thaçi D; Kimball A; Foley P; Poulin Y; Levi E; Chen R; Feldman SR
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):498-506. PubMed ID: 27538241
[TBL] [Abstract][Full Text] [Related]
20. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
Rich P; Gooderham M; Bachelez H; Goncalves J; Day RM; Chen R; Crowley J
J Am Acad Dermatol; 2016 Jan; 74(1):134-42. PubMed ID: 26549249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]